Celldex Therapeutics Inc (CLDX) - Total Liabilities
Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has total liabilities worth $55.03 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Celldex Therapeutics Inc (CLDX) net asset momentum to track the company's year-over-year net asset growth rate.
Celldex Therapeutics Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Celldex Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Celldex Therapeutics Inc (CLDX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Celldex Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Celldex Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
American States Water Company
NYSE:AWR
|
USA | $1.67 Billion |
|
OceanaGold Corporation
F:RQQ
|
Germany | €647.50 Million |
|
NCsoft Corp
KO:036570
|
Korea | ₩962.71 Billion |
|
Aperam SA
MC:APAM
|
Spain | €1.97 Billion |
|
Central Depository Services (India) Limited
NSE:CDSL
|
India | Rs4.17 Billion |
|
H B Fuller Company
NYSE:FUL
|
USA | $3.15 Billion |
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
China | CN¥18.04 Billion |
|
National Storage REIT
AU:NSR
|
Australia | AU$2.49 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Celldex Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Celldex Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celldex Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celldex Therapeutics Inc (1985–2025)
The table below shows the annual total liabilities of Celldex Therapeutics Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $55.82 Million | +23.12% |
| 2024-12-31 | $45.34 Million | +24.36% |
| 2023-12-31 | $36.46 Million | +37.41% |
| 2022-12-31 | $26.53 Million | +5.37% |
| 2021-12-31 | $25.18 Million | -4.92% |
| 2020-12-31 | $26.48 Million | -8.39% |
| 2019-12-31 | $28.91 Million | -8.95% |
| 2018-12-31 | $31.75 Million | -59.94% |
| 2017-12-31 | $79.25 Million | -32.79% |
| 2016-12-31 | $117.93 Million | +148.38% |
| 2015-12-31 | $47.48 Million | +30.60% |
| 2014-12-31 | $36.35 Million | +33.16% |
| 2013-12-31 | $27.30 Million | -8.29% |
| 2012-12-31 | $29.77 Million | +1.69% |
| 2011-12-31 | $29.27 Million | -15.61% |
| 2010-12-31 | $34.69 Million | -47.91% |
| 2009-12-31 | $66.60 Million | +28.92% |
| 2008-12-31 | $51.66 Million | -8.88% |
| 2007-12-31 | $56.69 Million | -4.43% |
| 2006-12-31 | $59.32 Million | +281.16% |
| 2005-12-31 | $15.56 Million | +110.43% |
| 2004-12-31 | $7.40 Million | +118.46% |
| 2003-12-31 | $3.39 Million | -12.94% |
| 2002-12-31 | $3.89 Million | -52.67% |
| 2001-12-31 | $8.22 Million | -14.69% |
| 2000-12-31 | $9.63 Million | +289.97% |
| 1999-12-31 | $2.47 Million | -36.67% |
| 1998-12-31 | $3.90 Million | +11.43% |
| 1997-12-31 | $3.50 Million | +118.75% |
| 1996-12-31 | $1.60 Million | -36.00% |
| 1995-12-31 | $2.50 Million | -19.35% |
| 1994-12-31 | $3.10 Million | -22.50% |
| 1993-12-31 | $4.00 Million | +66.67% |
| 1992-12-31 | $2.40 Million | -14.29% |
| 1991-12-31 | $2.80 Million | 0.00% |
| 1990-12-31 | $2.80 Million | +12.00% |
| 1989-12-31 | $2.50 Million | -47.92% |
| 1988-12-31 | $4.80 Million | +29.73% |
| 1987-12-31 | $3.70 Million | -11.90% |
| 1986-12-31 | $4.20 Million | -26.32% |
| 1985-12-31 | $5.70 Million | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more